Premaitha Health is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome) and Trisomy 13 (Patau’s syndrome). The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA® test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctors’ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. Premaitha’s strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women.
Premaitha is listed on the London Stock Exchange’s Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|£257.7 k||£102.5 k||£132.3 k||£2.5 m|
Revenue growth, %
Cost of sales
|£555.2 k||£1.8 m|
|(£297.5 k)||£701 k|
Gross profit Margin, %
Operating expense total
|£4.7 m||£12.7 m|